These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34753779)

  • 21. Interpretation of clinical endpoints in trials of acute myeloid leukemia.
    Medeiros BC
    Leuk Res; 2018 May; 68():32-39. PubMed ID: 29524739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glasdegib for the treatment of adult patients with newly diagnosed acute myeloid leukemia or high-grade myelodysplastic syndrome who are elderly or otherwise unfit for standard induction chemotherapy.
    Goldsmith SR; Lovell AR; Schroeder MA
    Drugs Today (Barc); 2019 Sep; 55(9):545-562. PubMed ID: 31584572
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel therapies for AML: a round-up for clinicians.
    Swaminathan M; Wang ES
    Expert Rev Clin Pharmacol; 2020 Dec; 13(12):1389-1400. PubMed ID: 33412978
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA Approval Summary: (Daunorubicin and Cytarabine) Liposome for Injection for the Treatment of Adults with High-Risk Acute Myeloid Leukemia.
    Krauss AC; Gao X; Li L; Manning ML; Patel P; Fu W; Janoria KG; Gieser G; Bateman DA; Przepiorka D; Shen YL; Shord SS; Sheth CM; Banerjee A; Liu J; Goldberg KB; Farrell AT; Blumenthal GM; Pazdur R
    Clin Cancer Res; 2019 May; 25(9):2685-2690. PubMed ID: 30541745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
    Thomas X; Heiblig M
    Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
    [No Abstract]   [Full Text] [Related]  

  • 26. New and emerging therapies for acute myeloid leukaemia.
    Davis JR; Benjamin DJ; Jonas BA
    J Investig Med; 2018 Dec; 66(8):1088-1095. PubMed ID: 30127098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advances in treatment formulations for acute myeloid leukemia.
    Briot T; Roger E; Thépot S; Lagarce F
    Drug Discov Today; 2018 Dec; 23(12):1936-1949. PubMed ID: 29870791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
    Kantarjian HM; Kadia TM; DiNardo CD; Welch MA; Ravandi F
    Cancer; 2021 Apr; 127(8):1186-1207. PubMed ID: 33734442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell cycle inhibitors for the treatment of acute myeloid leukemia: a review of phase 2 & 3 clinical trials.
    Jammal N; Rausch CR; Kadia TM; Pemmaraju N
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):491-499. PubMed ID: 33161749
    [No Abstract]   [Full Text] [Related]  

  • 30. Differentiating the Differentiation Syndrome Associated with IDH Inhibitors in AML.
    Zeidner JF
    Clin Cancer Res; 2020 Aug; 26(16):4174-4176. PubMed ID: 32554513
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.
    Steensma DP; Abedi M; Bejar R; Cogle CR; Foucar K; Garcia-Manero G; George TI; Grinblatt D; Komrokji R; Ma X; Maciejewski J; Pollyea DA; Savona MR; Scott B; Sekeres MA; Thompson MA; Swern AS; Nifenecker M; Sugrue MM; Erba H
    BMC Cancer; 2016 Aug; 16():652. PubMed ID: 27538433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemtuzumab ozogamicin for treatment of newly diagnosed acute myeloid leukaemia: a systematic review and meta-analysis.
    Kharfan-Dabaja MA; Hamadani M; Reljic T; Pyngolil R; Komrokji RS; Lancet JE; Fernandez HF; Djulbegovic B; Kumar A
    Br J Haematol; 2013 Nov; 163(3):315-25. PubMed ID: 24033280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Forsaken Pharmaceutical: Glasdegib in Acute Myeloid Leukemia and Myeloid Diseases.
    Feld J; Silverman LR; Navada SC
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e415-e422. PubMed ID: 33547022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Boulevard of broken dreams: drug approval for older adults with acute myeloid leukemia.
    Sekeres MA; Steensma DP
    J Clin Oncol; 2012 Nov; 30(33):4061-3. PubMed ID: 23008302
    [No Abstract]   [Full Text] [Related]  

  • 35. Which novel agents for acute myeloid leukemia are likely to change practice?
    Pollyea DA
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):391-395. PubMed ID: 30466754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
    Stone RM; Manley PW; Larson RA; Capdeville R
    Blood Adv; 2018 Feb; 2(4):444-453. PubMed ID: 29487059
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
    Lee DJ; Zeidner JF
    Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
    [No Abstract]   [Full Text] [Related]  

  • 38. The amsacrine story: will it change the FDA policy?
    Ann Oncol; 1991 Apr; 2(4):240-1. PubMed ID: 1868014
    [No Abstract]   [Full Text] [Related]  

  • 39. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
    Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
    Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular drug resistance in childhood acute myeloid leukemia. A mini-review with emphasis on cell culture assays.
    Kaspers GJ; Zwaan CM; Pieters R; Veerman AJ
    Adv Exp Med Biol; 1999; 457():415-21. PubMed ID: 10500817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.